China’s 2023 odyssey: economy grows by 5.2 per cent, population declines by two million January 17, 2024 China's economy grew by 5.2% in 2023, but a 2 million population decline highlighted challenges from a slowing property market and demographic pressures.
Rio Tinto: We are in state of ‘chronic unease’ over safety at our mines January 16, 2024 Mining giant Rio Tinto has pinned stimulus packages for the Chinese economy as drivers for a "gradual recovery" through 2024 despite key areas remaining weak.
More billionaires, less poverty – this isn’t a zero sum game, no matter what Oxfam claim January 16, 2024 German historian, sociologist and author Rainer Zitelmann argues billionaires and poverty are not involved in a zero-sum battle
Moving markets: Five things shaping the FTSE 100 today January 16, 2024 Asian stocks decline, the greenback strengthens, and oil prices surge amidst rising Middle East tensions. Focus sharpens on the UK labor market data.
UK bosses much more optimistic about 2024 than last year, PwC survey suggests January 15, 2024 PwC's annual global CEO survey showed that 39 per cent of UK bosses expect the economy to improve in 2024, up from just nine per cent last year.
FTSE 100 today: London markets brace for muted start amid thin U.S. holiday trading January 15, 2024 Asian markets decline in response to sparse U.S. holiday trading; China's central bank maintains stable lending rate; investor attention shifts towards Q3 earnings and China's Q4 GDP figures,
China’s central bank unexpectedly keeps lending rates steady; stocks recover from early slump January 15, 2024 The People's Bank of China has defied market expectations of providing a much-needed economic boost through additional easing measures by opting to maintain a crucial interest rate unchanged.
Market trends: The top five things on investors’ minds for 2024 January 12, 2024 As the investment industry undergoes huge change, Mitesh Sheth looks at the top five trends being eyed by equity investors in 2024.
GSK to spend up to £1.1bn in deal for access to unique asthma treatment January 9, 2024 GSK, formerly known as Glaxosmithkline, has agreed to acquire biopharmaceutical company Aiolos Bio in a deal worth at least $1bn (£785m), as it hails access to the latter company's twice-yearly asthma treatment.
The Notebook: Victoria Scholar on why 2024 might be a reality check for investors January 9, 2024 Victoria Scholar, head of investment at Interactive Investor, on what markets can expect from 2024, if January's anything to go by.